MacroGenics (MGNX)

• Market cap: $205M
• 1 day: 0.93%
• 5 days: -3.26%
• 1 month: -0.91%
• 3 months: 8.67%
• 6 months: -27.56%
• Year to date: -67.98%
• 1 year: -67.75%
• 5 years: -70.97%
• 10 years: -90.12%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Employees: 339

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

39% more call options, than puts

Call options by funds: $1.16M | Put options by funds: $835K

8.89% less ownership

Funds ownership: 97.81% [Q2] → 88.93% (-8.89%) [Q3]

15% less funds holding

Funds holding: 144 [Q2] → 122 (-22) [Q3]

17% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 46

28% less capital invested

Capital invested by funds: $260M [Q2] → $188M (-$72.7M) [Q3]

59% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 37

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 23% upside
• Avg. target: $4 23% upside
• High target: $4 23% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 24% 1-year accuracy 37 / 155 met price target

23% upside $4

Neutral Reiterated

6 Nov 2024